Wednesday , March 22 2023

Small blood drops, great medical benefit


Chuck Norris

Over the past few years, billions of dollars have been allocated to eliminate malignant neoplasms. We know the importance and importance of achieving this goal. We accept and support it. The less important thing we need to know is the need for effective treatment with other destructive illnesses: Alzheimer's. Annually, breast cancer and prostate can kill more people than malignant neoplasms. Several tests have not been able to detect, rebuild, or slow down the medication. According to the Alzheimer's Association of Voluntary Health Care Alzheimer Healthcare, the cost of medical care for Alzheimer's and other dementia in 2019 will reach $ 290 billion. If treatment or effective treatment is not found by 2050, these costs can reach $ 1.1 trillion. At present Alzheimer is home to 5.8 million Americans. Every 65 seconds in the United States, one develops disease. By 2050 this figure is expected to reach about 14 million.

Last month, at the Alzheimer Association's international conference, scientists presented their long-awaited goal: blood tests for people with Alzheimer's disease and other symptoms of dementia. A small amount of bleeding may be expected to predict Alzheimer's commencement and improve care and preventive measures. It would not have been revolutionary.

As reported in the Associated Press report, doctors are eager to use dementic symptoms during regular examinations to measure the effectiveness of those who require extensive testing. Semi-research teams at the conference gave new results in practical trials to provide such tools. Last year, a study by Japanese researchers revealed 92 percent of Alzheimer's patients and 85 percent correctly. The overall accuracy rate was 88 percent.

Due to dozens of trials today, clinical trials have failed. One part of the problem is that people are involved in the tests after too many brain damage. Along with Alzheimer's, many other topics were related to health. The diagnosis of this disease is traditionally based on the search for Alzheimer's symptoms. At this stage the illness is well developed. Doctors hope that blood tests will help people get better. This simple test can provide a warning system to people who need dozens of years before the onset of the disease.

It is assumed that recent blood tests will be used for federal funding research and selection of people. It should be borne in mind that such screening studies can take up to three years before even too much excitement, even on a fast track. Medical science doubts how Alzheimer's begins and develops. It seems that the normal size of certain proteins plays a big role. At present, expensive and invasive brain cerebral and extracellular extraction of spinal fluid is a means to measure the levels of these proteins. Both procedures are too costly, problematic, and can not be checked for a regular doctor.

These procedures also provide other issues. Shortly after the PET probe was discovered in 2013, Medicare officials found that it had no evidence of its health benefits. As a result, Medicare does not cover substantial costs of scanning; According to the Alzheimer's Association, private insurers do not oppose it.

Since Alzheimer's brain is known to be a few years before symptoms occur, it is of concern that patients and their family may refer to PET to find out if they have these biological markers. The Associated Press last year survey found that most Americans wanted to know the gene-linked gene, even if it had not been cured.

The problem is that these indicator proteins or neuronal structures appear often when they are aging. Not all of them develop the same dementia. Negative PET scanning does not mean that someone does not develop dementia.

"If we begin to treat everyone with clinical Alzheimer's disease, we are treated with many people who never go to dementia," Dr. Kenneth Langa, a researcher at the University of Michigan, and author of the latest article. recently diagnosed with Alzheimer's disease, which was recently published in The New York Times. "I hope we are thinking of unpleasant surprises."

It is also true that two main drugs approved for Alzheimer's have limited benefits for some patients over a limited period of time. No drug is effective for mild cognitive impairment, often a dementia-induced prophylaxis. Recently published Medicare research shows that PET can lead to more and more use of these and other drugs, regardless of the limited or limited benefits of scanning.

All the noise that causes this discussion will not allow us to predict the beginning of Alzheimer's and lose the hope that blood drops will be sufficient to improve care and preventive measures. Knowing that effective treatments are the way to change your sleep, diet, and exercise-related lifestyle that can help reduce or prevent Alzheimer's commencement. A recent study reveals the benefits of such changes.

According to Time magazine, scientists at the Rush University Medical Center in Chicago spent about ten years observing about 2,500 people. They claimed to have a healthy lifestyle – those who adhere to a non-obsessive diet, non-smoking, at least 150 minutes a week, engaged in physical activity, moderately drinking, and engaged in some vital cognitive activities. – There were low levels of Alzheimer's dementia. The higher the health of people, the less their risk. When we grow older, it is important that we live according to this prescription.

Ask Chuck Norris about your health and fitness questions. Watch Chuck Norris through his official social networking sites, Twitter @chucknorris, and the official Chuck Norris page on Facebook. He blogs at

wnd-charity-graphics-2-2019 "width =" 600 "height =" 600 "srcset =" -2019.jpeg 600w, 150w, /wp-content/uploads/2019/07/wnd-donation-graphic-2-2019-300x300.jpeg 300w, graphics-2-2019-275x275.jpeg 275w, 63w, https: // 86w sizees = "(max. width: 600px) 100vw, 600px" /></p>
<p><script>(function(d, s, id) {
  var js, fjs = d.getElementsByTagName(s)[0];
  if (d.getElementById(id)) return;
  js = d.createElement(s); = id;
  js.src = [ad_2]
Source link